Recent analysis
ABHA Covers 93 Crore Patients. Its Doctor Registry Covers 67%, and Insurers Aren't Required to Use the Claims Exchange Yet
September 17, 2026
India's ABHA has 93+ crore patient accounts — a bigger number than Estonia's entire population, several times over. But the two ...
Read the piece →Jan Aushadhi Sells 2,439 Products. Here's What We Actually Know About Where Their APIs Come From.
September 16, 2026
The Jan Aushadhi scheme now sells 2,439 products — 2,125 medicines and 314 surgical items — at Kendras across India, priced 50–80% below...
Read the piece →Sun Pharma's $11.75bn Organon Bet Is Bigger Than the RBI Rule Written to Fund It
September 16, 2026
Sun Pharma's $11.75 billion agreed purchase of Organon & Co. is the largest outbound deal an Indian pharmaceutical company has e...
Read the piece →India's Semaglutide Patent Cliff: 26 Brands in Weeks, a Price War, and a Government Crackdown
September 16, 2026
Semaglutide's Indian patent expired on 20 March 2026; within weeks, 13 companies had launched 26 branded generics, Novo Nordisk cut ...
Read the piece →Dr. Reddy's Cut Its Semaglutide Guidance in Half After an API Impurity It Caught Itself
September 16, 2026
A scale-up batch of Dr. Reddy's own synthetic semaglutide API tested out of specification in July 2026 — not a regulator's findi...
Read the piece →Contact Us
Umashankar Triplicane Dwarakanathan
Investment Promotion & Energy-Sector Leader · Chennai, Tamil Nadu, India